Document: NUREG-1555
Document ID: 68f32ac9-8d1d-4243-8e32-3aa120bfd4e5
Document Type: esrp
Title: EXPOSURE PATHWAYS
Source: NUREG-1555
Source URL: https://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1555/initial/
Revision Date: 2007-10
Chapter: 5
Section ID: 5.4.1
CFR Part: 
CFR Title: 

Content:
from the GASPAR code is due to noble gases and is not included in the iodine and particulate release pathways. Identify the receptor location for these doses. (4) For liquid effluents, from the LADTAP output, determine the maximum total body and organ dose to an individual. This dose should be for the age group (adult, teenager, or child) receiving the highest dose. It should be the sum of the pathways that are present in the vicinity of the site, although not necessarily at the same location. Thus, an individual fishing in the plant outfall region is assumed to be obtaining drinking water from the nearest potable water intake affected by plant operation. Identify the receptor location for these doses. (5) From the GASPAR and LADTAP outputs, determine the dose to the total body from all pathways and the dose to any organ from all pathways. (6) Compare the dose data from Items 2 through 5 (above) with the dose data calculated by the applicant. For significant differences, consult with the reviewer for ESRP 3.5 and with the applicant to determine the reasons for these variations. (7) Consult with the reviewer for ESRP 3.5 to determine if the dose commitments calculated above meet the design objectives of Appendix I to 10 CFR 50. If the reviewer for ESRP 3.5 determines that the dose does not meet these design objectives, the following procedure should be used: ` Ask the reviewer for ESRP 5.4.1 to re-evaluate the exposure pathway data. The objective of this re-evaluation is to determine if conservative estimates have been used, and if so, to see if more realistic pathway data can be identified that would result in decreased dose predictions. When more realistic input data can be identified, repeat the preceding review procedures of this ESRP and provide the reviewer for ESRP 3.5 with the revised dose calculations. ` If, upon re-analysis, the exposure pathway data are shown to be realistic and still result in a prediction that doses will not meet 10 CFR 50 design